# **Detection of Hypoglycemia and Hyperglycemia Using Noninvasive Wearable Sensors: Electrocardiograms and Accelerometry**

https://doi.org/10.1177/19322968221116393 DOI: 10.1177/19322968221116393 Journal of Diabetes Science and Technology 2024, Vol. 18(2) 351–362 © 2022 Diabetes Technology Society Article reuse guidelines: [sagepub.com/journals-permissions](https://us.sagepub.com/en-us/journals-permissions) [journals.sagepub.com/home/dst](https://journals.sagepub.com/home/dst)



Darpit Dave, MS<sup>1</sup>, Kathan Vyas, MS<sup>2</sup>, Kimberly Branan, MS<sup>3</sup>, **Siripoom McKay, MD4,5, Daniel J. DeSalvo, MD4,5, Ricardo Gutierrez-Osuna, PhD<sup>2</sup>, Gerard L. Cote, PhD<sup>3</sup> <b>D**, **and Madhav Erraguntla, PhD1**

### **Abstract**

**Background:** Monitoring glucose excursions is important in diabetes management. This can be achieved using continuous glucose monitors (CGMs). However, CGMs are expensive and invasive. Thus, alternative low-cost noninvasive wearable sensors capable of predicting glycemic excursions could be a game changer to manage diabetes.

**Methods:** In this article, we explore two noninvasive sensor modalities, electrocardiograms (ECGs) and accelerometers, collected on five healthy participants over two weeks, to predict both hypoglycemic and hyperglycemic excursions. We extract 29 features encompassing heart rate variability features from the ECG, and time- and frequency-domain features from the accelerometer. We evaluated two machine learning approaches to predict glycemic excursions: a classification model and a regression model.

**Results:** The best model for both hypoglycemia and hyperglycemia detection was the regression model based on ECG and accelerometer data, yielding 76% sensitivity and specificity for hypoglycemia and 79% sensitivity and specificity for hyperglycemia. This had an improvement of 5% in sensitivity and specificity for both hypoglycemia and hyperglycemia when compared with using ECG data alone.

**Conclusions:** Electrocardiogram is a promising alternative not only to detect hypoglycemia but also to predict hyperglycemia. Supplementing ECG data with contextual information from accelerometer data can improve glucose prediction.

#### **Keywords**

electrocardiogram (ECG), accelerometer data, noninvasive blood glucose monitoring, quantile regression, random forests, hypoglycemia, hyperglycemia

## **Introduction**

Diabetes is a serious health condition that affects nearly 422 million lives across the globe.<sup>1</sup> In a recent report by Centers for Disease Control and Prevention (CDC), one in ten individuals in the United States has diabetes.<sup>2</sup> Managing diabetes involves keeping blood glucose in an ideal range. $3,4$ Hypoglycemia, defined as having glucose levels below 70 mg/dL,<sup>5</sup> poses an acute danger that, if untreated, can result in loss of consciousness, seizures, and, in extreme cases, death.<sup>6</sup> In contrast, hyperglycemia, defined as glucose levels above 180 mg/dL, $3$  can lead to long-term complications such as heart disease, stroke, blindness, amputation, kidney disease,

dental disease, and increased susceptibility to infections.<sup>7</sup> Studies have shown correlations of time in range (70-180 mg/dL) with diabetes complications.<sup>3,8</sup> In this study, 70 mg/ dL was used as threshold for hypoglycemia and 180 mg/dL was used as threshold to define hyperglycemia.

Continuous glucose monitors (CGMs) provide frequent and automated glucose readings, and have improved glycemic control and resulted in effective diabetes management<sup>9</sup> compared with finger-stick glucose measurements. This can largely be attributed to key features of CGM devices—near real-time glucose readings and predictive low-glucose alerts.10 However, CGMs require the insertion of a sensor subcutaneously. The sensor needs to be replaced every 7 to

14 days and can cause discomfort.<sup>11</sup> Furthermore, individuals with prediabetes and type 2 diabetes typically do not get prescribed CGMs but may still benefit from having access to detailed glycemic patterns. Thus, noninvasive approaches for estimating glycemic excursions can be beneficial for a broad range of patients for whom CGMs are not an option.

A number of studies have analyzed whether glucose levels induce changes in physiological features.<sup>11,12</sup> The most common approaches include electrical and optical measurements such as electrocardiogram (ECG), photoplethysmography (PPG), near-infrared (NIR) spectroscopy, electrical bioimpedance, and skin temperature.12 Among these, ECG is a promising solution for detecting glucose levels.13-16 Previous studies have shown that glucose levels induce changes in the morphology of the QRS complex of the ECG, such as corrected QT intervals, and changes in QT intervals and RT-amplitude ratio, $17-21$  as well as changes in heart rate and heart rate variability  $(HRV).^{22,23}$ 

Most of the prior work using noninvasive physiological sensors has focused on detecting hypoglycemia as it has critical acute consequences.13,24,25 As noted earlier, however, the goal of diabetes management is not only to prevent the immediate consequences of hypoglycemia, but also to avoid the long-term complications associated with hyperglycemia.<sup>26</sup> Detecting hyperglycemia is straightforward when using CGMs, but noninvasive alternatives to detect hyperglycemia have not been broadly investigated. In addition, physical activity influences glucose patterns significantly.<sup>27-31</sup> For example, exercise can potentially lead to hypoglycemia. Furthermore, incorrect management of either insulin or food intake can lead to possible hyperglycemia. This suggests that analyzing the association between physical activity and glycemic levels might be used to detect hypoglycemic and hyperglycemic events. To our knowledge, no prior work has examined supplementing ECG data with contextual data from accelerometry to detect glucose levels in the hypoglycemic and hyperglycemic ranges.

The contributions of our work are: (1) detection of both hypoglycemia and hyperglycemia using noninvasive physiological sensors (ECG), and (2) using contextual information from accelerometer data to supplement ECG information for improved predictions. The prediction results are validated using CGM data as the ground truth.

# **Methods**

### *Data Description*

The data set used in this article was collected by a team of UK-based researchers.<sup>21</sup> The data included eight healthy participants and were recorded over a period of 14 consecutive days in normal living conditions. However, a portion of the actual data for a subgroup of patients became corrupted at the original data collector site, so our current study is based on data from five participants (IDs: 3, 4, 5, 6, and 7 from the original data set). More details on the data set are provided in the supplementary information (Supplemental Appendix I). The subjects included in the present study were three men and two women, aged 27 to 58 years (mean, 42.6 years). Two participants experienced hypoglycemia and two experienced hyperglycemia incidents during the study (Supplemental Appendix I).

Electrocardiogram signals were recorded using a Medtronic Zephyr BioPatch<sup>32</sup> at 250 Hz frequency. The BioPatch also measured accelerometer data in the vertical, lateral, and sagittal directions at 100 Hz. Continuous glucose monitor readings were recorded with a FreeStyle Libre Flash glucose monitor<sup>33</sup> at 15-minute intervals.

# *ECG Feature Extraction*

Electrocardiogram signals are vulnerable to distortions caused by motion artifacts.<sup>16,34,35</sup> As such, they require rigorous processing to filter out noise, especially when data are collected in free-living conditions.13 To overcome these challenges, we processed the raw ECG signal in three steps to extract HRV features. In the first step, we passed the ECG signal through a high-pass filter above 0.5 Hz to remove baseline wander. In the second step, we applied a continuous wavelet transform with a Ricker wavelet at a center frequency of 0.25 Hz to attenuate auxiliary peaks and make the R peaks more prominent. As shown in Figure 1, these two steps made it easier to detect R peaks in the ECG signal and were consistent with prior literature on handling motion artifacts and noise in ECG data. $36,37$  In the last step, we detected R peaks using the NeuroKit2 toolbox.<sup>38</sup> Once the R peaks were identified, we extracted nine HRV features (Table 1) based on these peaks. These HRV features were extracted for every one-minute window of ECG data. For each CGM

1 Wm Michael Barnes '64 Department of Industrial and Systems Engineering, Texas A&M University, College Station, TX, USA

#### **Corresponding Author:**

Madhav Erraguntla, PhD, Wm Michael Barnes '64 Department of Industrial and Systems Engineering, Texas A&M University, 4021 Emerging Technology Building, College Station, TX 77843, USA. Email: [merraguntla@tamu.edu](mailto:merraguntla@tamu.edu)

<sup>2</sup> Department of Computer Science and Engineering, Texas A&M University, College Station, TX, USA

<sup>&</sup>lt;sup>3</sup>Department of Biomedical Engineering, Texas A&M University, College Station, TX, USA

<sup>4</sup> Baylor College of Medicine, Houston, TX, USA

<sup>&</sup>lt;sup>5</sup>Texas Children's Hospital Clinical Care Center, Houston, TX, USA



**Figure 1.** Electrocardiogram signal preprocessing: (left) raw signal, (middle) after high-pass filtering, and (right) after applying the continuous wavelet transform.



Feature	Description
<b>HR</b>	Beats per minute/mean heart rate
<b>SDNN</b>	Standard deviation of NN intervals
<b>SDSD</b>	Standard deviation of successive differences
<b>RMSSD</b>	Root mean square of successive differences
<b>PNNI 20</b>	Proportion of successive differences over 20 ms
<b>PNNI 50</b>	Proportion of successive differences over 50 ms
HR MAD	Mean absolute deviation of RR intervals
<b>CVNN</b>	Coefficient of variation of NN intervals (SDNN/Mean NN)
<b>CVSD</b>	Coefficient of variation of successive differences (RMSSD/Mean NN)

**Table 2.** Accelerometer Features.



measurement, we used the HRV features in a lookback period of five minutes, that is ECG features for every one-minute window were concantenated for the previous five minutes. Thus, a total of 45 ECG features are used in the analysis.

### *Accelerometer Feature Extraction*

For the accelerometer, we extracted features in the time and frequency domains. In addition, we computed pairwise correlations between the three axes. The accelerometer features are shown in Table 2. Similar to ECG, accelerometer features



**Figure 2.** Lag and lookback periods to extract features from accelerometer data.

were extracted for each one-minute time window, but in this case using lookback periods of 5, 10, and 15 minutes. Because the effect of physical activity in blood glucose can take several minutes,<sup>39</sup> we also examined different time lags of 0, 5, 10, and 15 minutes to pair glucose and accelerometer data. The concepts of lag and lookback period/windows are depicted in Figure 2. Overall, this resulted in 12 different combinations of lag and lookback periods. Performance was evaluated for different combinations of lags and lookback periods for the fusion (ECG + Accelerometer) model (Supplemental Appendices II and III).

# *Data Cleaning and Handing Missing Values*

The original study focused on nocturnal hypoglycemia, whereas we consider both diurnal and nocturnal glycemic excursions. The Zephyr BioPatch records two data quality parameters from the ECG signal: the HR confidence and the ECG noise. These supplementary measures can be used to identify good ECG segments. Following the original work, $^{21}$ we selected ECG segments with a 100% confidence and ECG noise <0.001 for analysis. After this step, each data segment comprised a reference CGM time stamp and the ECG features from the previous five minutes. Electrocardiogram features were calculated for every one-minute window, resulting in five-time lagged ECG features corresponding to a CGM value. We discarded segments with more than 50% of missing data for a feature. For the retained segments, we estimated

Variable	Hypoglycemia		Normal		Hyperglycemia		<b>ANOVA</b>	
	Mean	<b>STD</b>	Mean	<b>STD</b>	Mean	<b>STD</b>	<b>F</b> statistic	P value
Heart rate	56.57	5.4	69.46	15.08	82.45	13.93	455.55	< .001
<b>CVNN</b>	0.07	0.056	0.1	0.09	0.08	0.09	28.01	< .001
<b>PNNI 20</b>	64.06	12.13	51.08	25.02	26.49	25.4	410.64	< .001
<b>PNNI 50</b>	35.35	17.26	26.89	23.03	12.43	19.37	175.08	< .001
HR MAD	71.65	59.22	95.23	430.11	39.66	45.5	6.72	.001
<b>CVSD</b>	0.06	0.04	0.08	0.11	0.07	0.11	5.36	.004
<b>SDNN</b>	75.85	55.48	111.72	525.74	56.73	60.42	5.011	.006
<b>SDSD</b>	65.66	41.58	99.72	636.42	51.69	74.78	2.712	.06
<b>RMSSD</b>	65.09	41.22	105.81	738.74	51.39	74.34	2.66	.07

Table 3. Electrocardiogram Features/ Statistics Across Hypoglycemia, Hyperglycemia, and Normal Ranges.

Abbreviations: ANOVA, analysis of variance; CVNN, coefficient of variation of NN intervals; CVSD, coefficient of variation of successive differences; HR MAD, mean absolute deviation of RR intervals; PNNI\_20, proportion of successive differences over 20 ms; PNNI\_50, proportion of successive differences over 50 ms; RMSSD, root mean square of successive differences; SDNN, standard deviation of NN intervals; SDSD, standard deviation of successive differences; STD, standard deviation. *P* values < 0.05 are bolded.

any missing data points by averaging the feature in that segment. For example, if a five-minute window is missing the HR estimate for the third minute, we estimated it by taking the mean of the first-, second-, fourth-, and fifth-minute HR values. Accelerometer data were not filtered, and no additional data cleaning steps were applied.

### *Exploratory Data Analysis*

In the first step, we computed statistical summaries of ECG and accelerometer features across the hypoglycemia, hyperglycemia, and normal glucose ranges. Then, we performed analysis of variance (ANOVA) to determine whether there were statistical differences between ECG and accelerometer features in the three glycemic ranges. Results are summarized in Tables 3 and 4. Most of the *P* values are less than .05, indicating that there are statistically significant differences between the mean values of the features in the three glycemic ranges. For ECG data, the patterns in the occurrence of R peaks and related HRV measures that capture these patterns are significantly different in the three glucose ranges. In addition, accelerometer data have various measures, especially in the time domain, that show differences among the glycemic ranges. This provides support for the use of ECG and accelerometer data to predict hypoglycemia and hyperglycemia.

### *Machine Learning Methodologies*

In the next step, we developed prediction models by combining data from all patients (population-level model). We explored two approaches to predict hypoglycemia and hyperglycemia: a classification model and a regression model.

The classification approach was based on random forests (RFs), an ensemble classifier that builds a large number of decision trees via bootstrapping. Bootstrapping is repeated

sampling of the data with replacement. In the case of RFs, multiple decision trees are built based on subsets of the entire data set through bootstrapping. The final prediction is derived based on a majority voting scheme across individual predictions from all the decision trees. In this majority voting scheme, outputs from all decision trees in the forests are aggregated, and the most common prediction across all the trees is chosen. We selected the RF model owing to its performance in similar applications.<sup>6,10</sup> In addition, the RF model provides a mechanism to identify significant features for prediction through the variable importance rankings as presented in the Results section.

The regression approach was based on quantile regression forests (QRFs), which are a generalization of RFs. Unlike RFs, which provide a single point estimate, QRFs provide a vector of estimates, one estimate for each quantile in the conditional distribution of the response variable. To illustrate, Figure 3 shows the spread of predicted values at different quantiles for three examples whose underlying glucose values were in the hypoglycemic, normal, and hyperglycemic ranges. As shown, quantile predictions when the underlying glucose is in the hypoglycemic range are lower than those in the normal range, which in turn are lower than those in the hyperglycemic range. Which of the quantile estimates is used for prediction depends on the application. For instance, if the goal is to minimize false negatives in hypoglycemia, then the prediction from a lower quantile should be selected.

### *Validation Mechanism*

For validation purposes, we partitioned data from each patient into a training and a testing set using a fivefold crossvalidation procedure. First, we ordered the data based on time stamps and divided it into five equal partitions for each patient. In each iteration, one partition of every patient was

		Hypoglycemia		Normal		Hyperglycemia		<b>ANOVA</b>	
Category	Variable	Mean	<b>STD</b>	Mean	<b>STD</b>	Mean	<b>STD</b>	F statistics	P value
Time domain	Mean	2051.83	49.2	2038.13	48.83	2049.04	47.06	15.54	$.001$
	<b>Minimum</b>	2038.35	50.8	2015.87	58.99	2029.16	55.86	28.85	$.001$
	Maximum	2062.35	51.8	2057.8	49.32	2066.19	49.91	7.62	$.001$
	<b>STD</b>	2.96	7.17	5.34	7.2	4.49	6.39	17.26	< 0.01
	No. of peaks	1202.51	169.65	142.96	191.92	142.02	198.77	13.29	< 0.01
	Kurtosis	13.48	21.46	7.51	16.53	13.14	107.05	12.02	< .001
	<b>IQR</b>	3.89	12.72	6.26	11.3	5.44	9.81	9.61	$.001$
	Signal magnitude area	12.31	0.3	12.22	0.3	12.29	0.28	19.44	$.001$
	<b>MAD</b>	1.16	1.79	2.57	4.06	2.09	2.75	19.66	$.001$
	<b>Skewness</b>	0.02	1.29	0.06	1.06	0.11	1.27	0.7	.5
Frequency	Maximum frequency	1.56	1.23	1.28	1.29	1.04	1.78	13.83	$.001$
domain	No. of peaks	33.3	2.6	33.03	2.7	33.34	2.52	3.82	.02
	Mean	0.09	0.32	0.49	3.99	0.33	0.89	1.72	.18
	Power	4.71	16.35	24.59	201.18	16.68	44.82	1.73	.18
	<b>STD</b>	0.41	2.08	2.41	26.77	1.31	3.75	1.14	.32
	Maximum	4.06	21.89	23	265.75	11.94	33.98	1.08	.33
Correlation	Vert_Lat	0.82	0.07	0.78	0.08	0.78	0.06	15.41	$.001$
pairs	Vert_Sag	0.79	0.13	0.74	0.12	0.81	0.12	28.31	$.001$
	Lat_Sag	0.86	0.11	0.82	0.09	0.86	0.06	14.48	$.001$

**Table 4.** Accelerometer Features/ Statistics Across Hypoglycemia, Hyperglycemia, and Normal Ranges.

Abbreviations: ANOVA, analysis of variance; IQR, interquartile range; MAD, mean absolute deviation; STD, standard deviation; Vert, vertical; Lat, lateral; Sag, sagittal. *P* values less than 0.05 are bolded.



**Figure 3.** Distribution of predictions per quantile for the quantile regression forest model (when trained with electrocardiogram data as input) when the ground-truth glucose level is in the hypoglycemic, normal, and hyperglycemic ranges.

used for testing and four partitions were used for training. The process was repeated five times, with each of the five partitions of each patient serving as test data in each iteration. The predictions across the five iterations were combined to report the model performance results. This validation strategy ensured that the training and test sets were from nonoverlapping time windows to avoid temporal correlations in the data yielding overly optimistic prediction results.<sup>10,40</sup>

### **Results**

For the classification model with fusion data (ECG  $+$ Accelerometer), a lookback period of five minutes with zero lag had the best performance on test data when area under curve (AUC) for hypoglycemia and hyperglycemia was averaged (Supplemental Appendix II). In contrast, for the regression model, a lookback period of ten minutes with zero lag gave the best performance for average AUC for hypoglycemia and hyperglycemia predictions (Supplemental Appendix III). From here on, fusion results reported in the article are based on this lag and lookback periods for fusion data (ECG + Accelerometer).

# *Performance of the Classifier Model (RF)*

We built two classifiers, one that discriminated between hypoglycemia (positive class) and all other measurements (negative class), and another classifier that discriminated hyperglycemia (positive) class from all other measurements (negative). When using only ECG features, we obtain an AUC of 0.76 and 0.82 for hypoglycemic and hyperglycemic detection, respectively. Combining features from ECG and accelerometer improves the AUC by 2% for hypoglycemia prediction and by 1% for hyperglycemia. Receiver operation characteristic (ROC) curves for hypoglycemia and hyperglycemia predictions are shown in Figure 4. From these ROC curves, we selected the equal error rate (EER) point to report



Figure 4. Receiver operation characteristic curves for (left) hypoglycemia and (right) hyperglycemia based on RF model. Abbreviations: AUC, area under curve; ECG, electrocardiogram; RF, random forest.

**Table 5.** Classification Performance Using Random Forests.

		Hypoglycemia		Hyperglycemia			
Data	<b>AUC</b>	Sensitivity	Specificity	<b>AUC</b>	Sensitivity	Specificity	
<b>ECG</b>	0.76	0.69	0.69	0.82	0.74	0.74	
Fusion	0.78	0.68	0.69	0.83	0.77	0.77	

Abbreviations: AUC, area under curve; ECG, electrocardiogram.

a single measure of sensitivity and specificity. Table 5 summarizes model performance using RFs. Adding accelerometer features had little effect for hypoglycemia detection but improves the sensitivity and specificity by 3% for hyperglycemia detection.

# *Performance of the Regression Model (Quantile RF)*

As noted earlier, QRFs provide a separate estimate of the glucose value for each quantile. To convert these quantile estimates into a label of hypoglycemia or hyperglycemia, we labeled each estimated glucose value as hypoglycemia if it was lower than 70 mg/dL and as hyperglycemia if it was greater than 180 mg/dL. Next, for each quantile, we computed the true positive rate (TPR) and false positive rate (FPR) on test data. Then, we generated an ROC curve by plotting the TPR against FPR for the different quantiles. Results are shown in Figure 5. As before, we selected the EER to report a unique value for sensitivity and specificity (Table 6). When using ECG data alone, the QRF model achieved 2% higher sensitivity and specificity than the RF classifier for both hypoglycemia and hyperglycemia detection. Furthermore, the QRF model based on fusion data outperformed the RF model based on fusion data by 8% (on sensitivity and specificity) for hypoglycemia and by 2% (on sensitivity and specificity) for hyperglycemia. When

accelerometer data were added to the QRF model, we observed a 5% (for hypoglycemia) and 3% (for hyperglycemia) improvement in sensitivity and specificity (Table 6) as compared with using ECG data alone. These improvements can be explained by the fact that accelerometer data can be used to detect physical activity, and hence can be correlated with glucose changes. As an example, an increase in HR without corresponding physical activity can be indicative of a hyperglycemic event, whereas a decrease in HR with normal physical activity can be indicative of a hypoglycemic event. Hence, accelerometer data provide contextual information to help interpret the ECG data. The best model, the QRF model based on fused data, had sensitivity and specificity of 76% for hypoglycemia, and sensitivity and specificity of 79% for hyperglycemia.

### *Feature Importance*

We examined the relative importance of the ECG and accelerometer features for predicting hyperglycemia and hypoglycemia. For this purpose, we used the RF model, which reports the importance of each feature based on reduction in model performance when a particular variable is excluded from a tree. In the case of ECG features, there are five-time lagged feature values (one for each minute in the previous five minutes) associated with a CGM value. The feature importance reported below is the average importance across the



**Figure 5.** Receiver operation characteristic curves for (left) hypoglycemia and (right) hyperglycemia based on QRF. Abbreviations: AUC, area under curve; ECG, electrocardiogram; QRFs, quantile regression forests.

**Table 6.** Classification Performance Using Quantile Random Forests.

		Hypoglycemia		Hyperglycemia		
Data	<b>AUC</b>	Sensitivity	Specificity	<b>AUC</b>	Sensitivity	Specificity
<b>ECG</b>	0.79	0.71	0.71	0.82	0.76	0.76
Fusion	0.83	0.76	0.76	0.87	0.79	0.79

Abbreviations: AUC, area under curve; ECG, electrocardiogram.

five-time lagged features. Similarly, for the accelerometer features, the average of importance in the lookback period of five minutes with zero lag is reported. Thus, both accelerometer feature importance and ECG feature importance are reported based on the average of five-time lagged features. For example, the importance score for the variable "Mean HR" is the average of importance scores for variable "Mean HR" that were one, two, three, four, and five minutes preceding the CGM reading.

Results for hypoglycemia are shown in Figure 6. There is clear evidence of accelerometer features such as the pairwise correlation pairs between three axis, kurtosis, and area to be among those highly ranked for hypoglycemia prediction. Results for hyperglycemia are shown in Figure 7. In this case, ECG features appear to be more dominant than accelerometer features.

# **Discussion**

### *Insights and Observations*

The feature importance plots (Figures 6 and 7) validate the importance of ECG data for detecting hypoglycemia and hyperglycemia, in agreement with the summary statistics and ANOVA tests in Tables 3 and 4. Together, these findings indicate that ECG features can be used to detect glycemic excursions, and that accelerometer data provide additional information $41,42$  that improves predictions.



**Figure 6.** Feature importance for random forests trained to predict hypoglycemia. Abbreviations: CVNN, coefficient of variation of NN intervals; CVSD, coefficient of variation of successive differences; HR, heart rate; HR MAD, mean absolute deviation of RR intervals; IQR, interquartile range; MAD, mean absolute deviation; PNNI 20, proportion of successive differences over 20 ms; PNNI 50, proportion of successive differences over 50 ms; RMSSD, root mean square of successive differences; SDNN, standard deviation of NN intervals; SDSD, standard deviation of successive differences; STD, standard deviation.

Our results show that QRF moderately outperforms RF when predicting both hypoglycemia and hyperglycemia. To illustrate this point, Figure 8 shows the ROC curves for the two types of classifiers (QRF, RF), feature sets (ECG, ECG

+ accelerometer), and prediction problems (hypoglycemia, hyperglycemia). For hypoglycemia prediction, the ROC curves indicate that the addition of accelerometer data as well as the choice of classifier is the contributing factor to higher performance. In contrast, for hyperglycemia prediction, it appears that the feature set  $(ECG + \text{accelerometer})$ , rather than the choice of classifier, is needed to improve performance.

The main contributions of our work to address the challenges for noninvasive detection of glucose levels can be summarized as follows:



**Figure 7.** Feature importance for random forests trained to predict hyperglycemia. Abbreviations: CVNN, coefficient of variation of NN intervals; CVSD, coefficient of variation of successive differences; HR, heart rate; HR MAD, mean absolute deviation of RR intervals; IQR, interquartile range; MAD, mean absolute deviation; PNNI 20, proportion of successive differences over 20 ms; PNNI 50, proportion of successive differences over 50 ms; RMSSD, root mean square of successive differences; SDNN, standard deviation of NN intervals; SDSD, standard deviation of successive differences; STD, standard deviation.

- 1. Detection of glucose levels in hypoglycemic and hyperglycemic ranges.
- 2. Use of accelerometer data to supplement ECG data to improve prediction performance.

### *Comparison With Previous Studies*

Finally, we provide a comparison of previous work for noninvasive prediction of glucose levels. For this purpose, we considered studies that reported results for hypoglycemia and hyperglycemia prediction. Results are summarized in Table 7. Electrocardiogram is the most widely used physiological signal. Other approaches include electroencephalogram, PPG, and galvanic skin responses. However, results based on data streams other than ECG have not been promising.<sup>43</sup> Recently, in 2018 and 2020, a data set was made publicly available through the Blood Glucose Level Prediction challenge at Ohio University,<sup>44</sup> which examined a variety of machine learning models to predict future glucose levels by analyzing the recent history of CGM readings. In addition to CGM recordings, the OhioT1DM data set includes physiological data such as heart rate, skin temperature, and activity-related data. However, no improvement in predicting glucose levels, and in some cases degradations in prediction performance, has been reported when combining physiological features and CGM history.45-50 A possible reason for this result is that physiological data in the OhioT1DM data set are aggregated (every one to five minutes) and hence it is not possible to extract the granular features we used in our study.

To the best of our knowledge, a recent study<sup>13</sup> is the only publication that used noninvasive ECG data to detect both hypoglycemia and hyperglycemia. They reported that ECG data are able to classify glucose levels in the hypoglycemia, hyperglycemia, and normal ranges. Comparing predictive performance across different studies in the literature is difficult due to differences in the data collected, prediction focus,



**Figure 8.** Receiver operation characteristic curves with ECG and ECG + accelerometer for the RF and QRF models. (Left) Hypoglycemia prediction. (Right) Hyperglycemia prediction.

Abbreviations: AUC, area under curve; ECG, electrocardiogram; QRFs, quantile regression forests; RF, random forest.



Table 7. Comparison of Previous Works on Noninvasive Detection of Blood Glucose Levels. **Table 7.** Comparison of Previous Works on Noninvasive Detection of Blood Glucose Levels.

Abbreviations: ECG, electrocardiogram; EEG, electroencephalogram; NIR, near-infrared; PPG, photoplethysmography. Abbreviations: ECG, electrocardiogram; EEG, electroencephalogram; NIR, near-infrared; PPG, photoplethysmography.

metrics used, and validation methods. A critical aspect when developing robust machine learning models is choosing an appropriate validation approach. Some prior studies have shown high levels of accuracy (both sensitivity and specificity) using a cross-validation based on random splitting.<sup>51,52</sup> Although this is a standard approach in machine learning, such a validation scheme may not be appropriate for this application because of temporal correlations in the data. We believe that the time-based validations we used in our study provide more realistic estimates of performance when the approach is deployed in the field. $10,40$ 

### *Limitations*

One limitation of our work is the limited data sample size. Our data set consisted of recordings for five participants over a period of 14 days, and the records only included 14 hypoglycemic episodes and 25 hyperglycemic episodes. To address this limitation, we carefully designed the training/ test set splitting criteria to avoid obtaining overly optimistic results. Namely, instead of splitting measurements randomly, which can lead to inflated results due to short-term temporal correlations in the data, we adopted a time-based splitting criterion where data in the training and test sets were from entirely different time periods. This ensured that the results are an accurate characterization of the performance that could be expected when the model is evaluated on new time periods for the existing subjects. To address the data availability issue, we are currently conducting a study to collect CGM and physiological data for 50 participants with type 1 diabetes. This new data set will provide measures from noninvasive wearable devices and include data streams, namely, ECG, respiration, PPG, electrodermal activity, accelerometer, skin temperature, and heart rate. This will allow us to examine whether other physiological modalities beyond ECG and accelerometer data, such as skin temperature and electrodermal activity, can further improve predictions. In this larger data set, it is possible to use more restrictive splitting criteria, such as a leave-one-subject-out procedure. Also, the current study is based on data collected from healthy participants and it is assumed that the results are transferable to population with diabetes.

# **Conclusion**

In this article, we proposed a noninvasive approach to detect glycemic excursions (hypoglycemia and hyperglycemia) from ECG and accelerometer data. We evaluated an RF classifier and a QRF regression model. For both approaches, models with fusion data (ECG and accelerometer) outperform models based on ECG data alone. The QRF model based on fusion data had a sensitivity and specificity of 76% for detecting hypoglycemia. This outperformed the RF model on fusion data by 8%. For hyperglycemic prediction, QRF with fusion data had a sensitivity and specificity of 79%, which outperformed the RF model by 2%. These results indicate that not only hypoglycemia but also hyperglycemia can be effectively detected from noninvasive physiological signals. This finding has important clinical implications for diabetes monitoring and management without the need for CGM devices. The results also show that contextual information from the accelerometer provides additional information for predicting glucose excursions.

#### **Abbreviations**

ANOVA, analysis of variance; AUC, area under curve; CGM, continuous glucose monitoring; CWT, continuous wavelet transform; ECG, electrocardiogram; EER, equal error rate; FPR, false positive rate; GSR, galvanic skin response; HR, heart rate; HRV, heart rate variability; NIR, near-infrared; PPG, photoplethysmography; QRFs, quantile regression forests; RFs, random forests; ROC, receiver operation characteristic; TPR, true positive rate; VIP, variable importance plot.

#### **Acknowledgments**

This study involves the use of secondary analysis of de-identified data that were not collected specifically for this project and is not human subject research. The views expressed here are those of the authors. This study would not have been possible without the kind assistance from Professors Leandro Pecchia and Salman Haleem from The University of Warwick (UK), who granted us access to the CGM and physiological data set from the original study.

#### **Declaration of Conflicting Interests**

The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: D.J.D. serves as an independent consultant for Dexcom separate from the present work. The remaining authors have no potential conflict of interests relevant to this article.

#### **Funding**

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by NSF award 2037383 (SenSE: Multimodal noninvasive wearable sensors and machine learning for predicting critical glycemic events).

### **ORCID iDs**

Gerard L. Cote **D** <https://orcid.org/0000-0002-3164-9625> Madhav Erraguntla **D** <https://orcid.org/0000-0003-0017-5866>

### **Supplemental Material**

Supplemental material for this article is available online.

### **References**

1. Ahuja R, Dixit P, Banga A, Sharma SC. Classification algorithms for predicting diabetes mellitus: a comparative analysis. In: Husain MS, Adnan MHBM, Khan MZ, Shukla S, Khan FU, eds. *Pervasive Healthcare: A Compendium of Critical Factors for Success*. Cham: Springer International Publishing; 2022:233-253.

- 2. Centers for Disease Control and Prevention. Type 2 Diabetes. 2021. <https://www.cdc.gov/diabetes/basics/type2.html>. Accessed January 24, 2022.
- 3. Battelino T, Danne T, Bergenstal RM, et al. Clinical targets for continuous glucose monitoring data interpretation: recommendations from the international consensus on time in range. *Diabetes Care*. 2019;42(8):1593-1603.
- 4. Mariani HS, Layden BT, Aleppo G. Continuous glucose monitoring: a perspective on its past, present, and future applications for diabetes management. *Clin Diabetes*. 2017;35(1):60-65.
- 5. American Diabetes Association. Hypoglycemia (Low Blood Glucose). diabetes.org. American Diabetes Association; 2022. [https://www.diabetes.org/healthy-living/medication-treatments/](https://www.diabetes.org/healthy-living/medication-treatments/blood-glucose-testing-and-control/hypoglycemia) [blood-glucose-testing-and-control/hypoglycemia](https://www.diabetes.org/healthy-living/medication-treatments/blood-glucose-testing-and-control/hypoglycemia). Accessed June 25, 2022.
- 6. Dave D, DeSalvo DJ, Haridas B, et al. Feature-based machine learning model for real-time hypoglycemia prediction. *J Diabetes Sci Technol*. 2021;15(4):842-855.
- 7. Qaraqe M, Erraguntla M, Dave D. AI and machine learning in diabetes management: opportunity, status, and challenges. In: Househ M, Borycki E, Kushniruk A, eds. *Multiple Perspectives on Artificial Intelligence in Healthcare: Opportunities and Challenges*. Cham: Springer International Publishing; 2021:129-141.
- 8. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. *Diabetes Care*. 2019;42(3):400-405.
- 9. Rodbard D. Continuous glucose monitoring: a review of recent studies demonstrating improved glycemic outcomes. *Diabetes Technol Ther*. 2017;19(S3):S25-S37.
- 10. Dave D, Erraguntla M, Lawley M, et al. Improved lowglucose predictive alerts based on sustained hypoglycemia: model development and validation study. *JMIR Diabetes*. 2021;6(2):e26909.
- 11. Villena Gonzales W, Mobashsher AT, Abbosh A. The progress of glucose monitoring—a review of invasive to minimally and non-invasive techniques, devices and sensors. *Sensors*. 2019;19(4):800.
- 12. Jain P, Joshi AM, Mohanty S. Everything you wanted to know about noninvasive glucose measurement and control. *arXiv*. 2021: arXiv:2101.08996. doi:10.48550/arXiv.2101.08996.
- 13. Li J, Tobore I, Liu Y, Kandwal A, Wang L, Nie Z. Noninvasive monitoring of three glucose ranges based on ECG by using DBSCAN-CNN. *IEEE J Biomed Health Inform*. 2021;25(9):3340-3350.
- 14. Schroeder EB, Chambless LE, Liao D, et al. Diabetes, glucose, insulin, and heart rate variability: the Atherosclerosis Risk in Communities (ARIC) study. *Diabetes Care*. 2005;28(3): 668-674.
- 15. Singh JP, Larson MG, O'Donnell CJ, et al. Association of hyperglycemia with reduced heart rate variability (The Framingham Heart Study). *Am J Cardiol*. 2000;86(3):309-312.
- 16. Valensi P, Extramiana F, Lange C, et al. Influence of blood glucose on heart rate and cardiac autonomic function. *Diabet Med*. 2011;28(4):440-449.
- 17. Ling SH, San PP, Lam HK, Nguyen HT. Hypoglycemia detection: multiple regression-based combinational neural logic approach. *Soft Comput*. 2017;21(2):543-553.
- 18. Ling SH, San PP, Nguyen HT. Non-invasive hypoglycemia monitoring system using extreme learning machine for type 1 diabetes. *ISA Trans*. 2016;64:440-446.
- 19. Ling SS, Nguyen HT. Genetic-algorithm-based multiple regression with fuzzy inference system for detection of nocturnal hypoglycemic episodes. *IEEE Trans Inf Technol Biomed*. 2011;15(2):308-315.
- 20. Lipponen JA, Kemppainen J, Karjalainen PA, et al. Hypoglycemia detection based on cardiac repolarization features. In: 2011 Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Boston, MA, USA. IEEE; 2011.
- 21. Porumb M, Stranges S, Pescapè A, Pecchia L. Precision medicine and artificial intelligence: a pilot study on deep learning for hypoglycemic events detection based on ECG. *Sci Rep*. 2020;10(1):1-16.
- 22. Cichosz SL, Frystyk J, Hejlesen OK, Tarnow L, Fleischer J. A novel algorithm for prediction and detection of hypoglycemia based on continuous glucose monitoring and heart rate variability in patients with type 1 diabetes. *J Diabetes Sci Technol*. 2014;8(4):731-737.
- 23. Gonzalez K, Sasangohar F, Mehta RK, Lawley M, Erraguntla M. Measuring fatigue through heart rate variability and activity recognition: a scoping literature review of machine learning techniques. In: *Proceedings of the Human Factors and Ergonomics Society Annual Meeting*. Los Angeles, CA: SAGE Publications; 2017.
- 24. Gabbay MAL, Rodacki M, Calliari LE, et al. Time in range: a new parameter to evaluate blood glucose control in patients with diabetes. *Diabetol Metab Syndr*. 2020;12:22-28.
- 25. Yang M, Dave D, Erraguntla M, Cote GL, Gutierrez-Osuna R. Joint hypoglycemia prediction and glucose forecasting via deep multi-task learning. In: ICASSP 2022-2022 IEEE International Conference on Acoustics, Speech and Signal Processing (ICASSP), Singapore. IEEE; 2022.
- 26. Abbas HT, Alic L, Erraguntla M, et al. Predicting long-term type 2 diabetes with support vector machine using oral glucose tolerance test. *PLoS One*. 2019;14(12):e0219636.
- 27. Moser O, Riddell MC, Eckstein ML, et al. Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type 1 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). *Diabetologia*. 2020;63(12):2501-2520.
- 28. Hosseinian SM, Zhu Y, Mehta RK, Erraguntla M, Lawley MA. Static and dynamic work activity classification from a single accelerometer: implications for ergonomic assessment of manual handling tasks. *IISE Trans Occup Ergon Hum Factors*. 2019;7(1):59-68.
- 29. Zhu Y, Mehta RK, Erraguntla M, Sasangohar F, Qaraqe K. Quantifying accelerometer-based tremor features of neuromuscular fatigue in healthy and diabetic adults. *IEEE Sens J*. 2020;20(19):11183-11190.
- 30. Aljihmani L, Kerdjidj O, Petrovski G, et al. Hand tremor-based hypoglycemia detection and prediction in adolescents with type 1 diabetes. *Biomed Signal Process Control*. 2022;78:103869.
- 31. Aljihmani L, Kerdjidj O, Zhu Y, et al. Classification of fatigue phases in healthy and diabetic adults using wearable sensor. *Sensors*. 2020;20(23):6897.
- 32. Technology ZPSPM. ZephyrTM Performance Systems, Performance Monitoring Technology. *Secondary ZephyrTM Performance Systems, Performance Monitoring Technology*

2022. [https://www.zephyranywhere.com/.](https://www.zephyranywhere.com/) Accessed July 19, 2022.

- 33. Blum A. FreeStyle Libre Glucose Monitoring System. *Clin Diabetes*. 2018;36(2):203-204.
- 34. Ding H, Sarela A, Helmer R, Mestrovic M, Karunanithi M. Evaluation of ambulatory ECG sensors for a clinical trial on outpatient cardiac rehabilitation. In: IEEE/ICME International Conference on Complex Medical Engineering, Gold Coast, Australia. IEEE; 2010.
- 35. Kim J-H, Roberge R, Powell J, Shafer A, Williams WJ. Measurement accuracy of heart rate and respiratory rate during graded exercise and sustained exercise in the heat using the Zephyr BioHarnessTM. *Int J Sports Med*. 2013;34(06):497-501.
- 36. Nathan V, Akkaya I, Jafari R. A particle filter framework for the estimation of heart rate from ECG signals corrupted by motion artifacts. In: 37th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), Milan, Italy. IEEE; 2015.
- 37. Nathan V, Jafari R. Particle filtering and sensor fusion for robust heart rate monitoring using wearable sensors. *IEEE J Biomed Health Inform*. 2017;22(6):1834-1846.
- 38. Makowski D, Pham T, Lau ZJ, et al. NeuroKit2: a Python toolbox for neurophysiological signal processing. *Behav Res Methods*. 2021;53(4):1689-1696.
- 39. Zaharieva DP, Turksoy K, McGaugh SM, et al. Lag time remains with newer real-time continuous glucose monitoring technology during aerobic exercise in adults living with type 1 diabetes. *Diabetes Technol Ther*. 2019;21(6):313-321.
- 40. Roberts DR, Bahn V, Ciuti S, et al. Cross-validation strategies for data with temporal, spatial, hierarchical, or phylogenetic structure. *Ecography*. 2017;40(8):913-929.
- 41. Aminian K, Robert P, Buchser EE, Rutschmann B, Hayoz D, Depairon M. Physical activity monitoring based on accelerometry: validation and comparison with video observation. *Med Biol Eng Comput*. 1999;37(3):304-308.
- 42. Long X, Yin B, Aarts RM. Single-accelerometer-based daily physical activity classification. In: 2009 Annual International Conference of the IEEE Engineering in Medicine and Biology Society, Minneapolis, MN, USA. IEEE; 2009.
- 43. Diouri O, Cigler M, Vettoretti M, et al. Hypoglycaemia detection and prediction techniques: a systematic review on the latest developments. *Diabetes Metab Res Rev*. 2021;37(7):e3449.
- 44. Marling C, Bunescu R. The OhioT1DM dataset for blood glucose level prediction: Update 2020. In *CEUR workshop proceedings* (Vol. 2675, p. 71). NIH Public Access; 2020.
- 45. Gadaleta M, Facchinetti A, Grisan E, Rossi M. Prediction of adverse glycemic events from continuous glucose monitoring signal. *IEEE J Biomed Health Inform*. 2018;23(2):650-659.
- 46. Mirshekarian S, Shen H, Bunescu R, Marling C. LSTMs and neural attention models for blood glucose prediction: comparative experiments on real and synthetic data. In: 2019 41st Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC), Berlin, Germany. IEEE; 2019.
- 47. Oviedo S, Vehí J, Calm R, Armengol J. A review of personalized blood glucose prediction strategies for T1DM patients. *Int J Numer Method Biomed Eng*. 2017;33(6):e2833.
- 48. Xie J, Wang Q. Benchmarking machine learning algorithms on blood glucose prediction for type I diabetes in comparison with classical time-series models. *IEEE Trans Biomed Eng*. 2020;67(11):3101-3124.
- 49. Yang J, Li L, Shi Y, Xie X. An ARIMA model with adaptive orders for predicting blood glucose concentrations and hypoglycemia. *IEEE J Biomed Health Inform*. 2018;23(3): 1251-1260.
- 50. Zecchin C, Facchinetti A, Sparacino G, Cobelli C. How much is short-term glucose prediction in type 1 diabetes improved by adding insulin delivery and meal content information to CGM data? A proof-of-concept study. *J Diabetes Sci Technol*. 2016;10(5):1149-1160.
- 51. Cichosz SL, Kronborg T, Jensen MH, Hejlesen O. Penalty weighted glucose prediction models could lead to better clinically usage. *Comput Biol Med*. 2021;138:104865.
- 52. Rashtian H, Torbaghan SS, Rahili S, Snyder M, Aghaeepour N. Heart rate and CGM feature representation diabetes detection from heart rate: learning joint features of heart rate and continuous glucose monitors yields better representations. In: IEEE Access. IEEE; 2021.